Medicxi

Life sciences venture capital firm

[Medicxi @medicxi]

Medicxi's investment in Curevo is a reflection of our continued conviction in vaccines and infectious disease as impactful areas in modern medicine.

We are excited to partner with @EliLillyandCo on the development of Curevo's next-generation shingles vaccine, Amezosvatein

[Medicxi @medicxi]

Thrilled to announce the acquisition of @CurevoVaccine by @EliLillyandCo for $1.5B 🚀

Congratulations to Moncef Slaoui, George Simeon and the entire Curevo team for achieving this milestone

https://t.co/zffl2Hfs9x

[Medicxi @medicxi]

We are proud to announce the acquisition of @centessa by @EliLillyandCo for a total of $7.8B

Congratulations to current CEO Mario Accardi, former CEO Saurabh Saha and the entire Centessa Team

https://t.co/rlDP2LA1Ja

[Medicxi @medicxi]

We are proud to unveil our latest fund Medicxi V

Through this €500M fund we will continue our dedicated support for innovative biotech companies and world-class drug hunters with clear product visions to transform patient care

https://t.co/P8e9qVnhyv

[Medicxi @medicxi]

This marks Servier’s first asset acquisition in neurology, and following a recent positive Ph1 study under the stewardship of Rob Ring and Kaerus’ team, Servier plans to commence Ph2 development in 2026

[Medicxi @medicxi]

Delighted to announce that KER-0193, a potential treatment for Fragile X syndrome being developed by Kaerus Bioscience, has been acquired by @Servier for up to $450M

Congratulations to Rob Ring and the entire Kaerus team for this fantastic outcome!

https://t.co/EUmmI21QeQ

[Medicxi @medicxi]

Kaerus is an asset-centric company founded by Medicxi, to develop small molecules that target the core pathology in Fragile X Syndrome by restoring aberrant neuronal potassium channel function in these patients

[Medicxi @medicxi]

Partnering with @sanofi will help accelerate clinical development of VXB-241 and next generation products

This is a fantastic outcome for the Vicebio platform and for patients suffering these viral respiratory infections

[Medicxi @medicxi]

Thrilled to announce that @medicxi portfolio company Vicebio has entered into an exclusive agreement to be acquired by @sanofi for $1.6B, including an upfront payment of $1.15B 🚀🚀

https://t.co/Do76ebQMSx

[Medicxi @medicxi]

Vicebio was created by @medicxi to develop next-generation vaccines for respiratory viruses, utilising its proprietary Molecular Clamp technology

The lead asset, VXB-241, is a bivalent vaccine targeting RSV and hMPV, currently in Phase 1 clinical development

[Medicxi @medicxi]

Rhinovirus infections account for >45% of COPD exacerbations and are associated with poorer outcomes for patients with COPD

Vapendavir has potent activity against 97% of rhinoviruses, and could help prevent the devastating consequences of rhinovirus-mediated COPD exacerbations

[Medicxi @medicxi]

In this placebo-controlled study, treatment with vapendavir was well tolerated, led to faster reduction in viral load and a shorter overall course of illness with fewer adverse and severe adverse respiratory events versus placebo

[Medicxi @medicxi]

Congratulations to the Altesa Biosciences team on reporting positive Phase 2 data for vapendavir in a Rhinovirus challenge study in patients with COPD

https://t.co/7eSY3xYFMe

[Medicxi @medicxi]

Medicxi is joined by other new investors OrbiMed, HBM Healthcare Investments and Sanofi Ventures, with participation of current insiders

Funding will support completion of Phase 2 development, with a clear path towards Phase 3 and market authorization

[Medicxi @medicxi]

Excited to announce that Medicxi has led Curevo Vaccine’s $110M Series B financing

As part of this financing, Giovanni Mariggi will join the board of directors, alongside vaccine industry leaders Moncef Slaoui and Tal Zaks

https://t.co/b79pSc2QmN

[Medicxi @medicxi]

Curevo is developing Amezosvatein, to address critical unmet needs in shingles vaccination

In Phase 2, Amezosvatein demonstrated competitive efficacy and potential for superior tolerability versus Shingrix, thanks to Curevo’s proprietary adjuvant technology

[Medicxi @medicxi]

Kaerus will advance KER-0193 into Phase 2 proof-of-concept study later this year, moving one step closer to providing a safe and efficacious therapy to patients with FXS

[Medicxi @medicxi]

Congratulations to Kaerus Bioscience for successfully completing Phase 1 development for KER-0193, a novel BK channel modulator for Fragile X syndrome (FXS)

https://t.co/ARhWKahtEQ

[Medicxi @medicxi]

KER-0193 was safe and well tolerated in 56 healthy volunteers, with positive pharmacodynamic effects confirmed in translationally relevant parameters by pharmaco-EEG